RINVOQ 45 mg prolonged-release tablets, Placebo to Match Blinded Upadacitinib, Entyvio 300 mg powder for concentrate for solution for infusion
Vedolizumab-3043
Approved small_molecule active
Quick answer
RINVOQ 45 mg prolonged-release tablets, Placebo to Match Blinded Upadacitinib, Entyvio 300 mg powder for concentrate for solution for infusion for Chron's Disease is a Approved program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Chron's Disease
- Phase
- Approved
- Modality
- small_molecule
- Status
- active